Optimer Pharma Sets Terms

Optimer Pharmaceuticals Inc., a San Diego-based developer of anti-infective products, has set its proposed IPO terms to 5.25 million common shares being offered at between $12 and $14 per share. It plans to trade on the Nasdaq under ticker symbol OPTR, with Piper Jaffray and Jefferies & Co. serving as co-lead underwriters. It has raised $67.7 million in VC funding from firms like ProQuest Investments, Formose Healthcare Investments and BB Biotech. www.optimerpharma.com